Kalia Health

Executive Summary

Kalia Health is a San Diego-based diagnostics company developing a non-invasive urine test for the early detection of preeclampsia, a hypertensive disorder of pregnancy that poses significant risks to both mother and fetus. In a major milestone, the company was awarded a Grand Challenges Grant from the Bill & Melinda Gates Foundation, which will support the advancement of its urinary biomarker platform. This grant underscores the potential clinical and global health impact of Kalia Health's approach, particularly in low-resource settings where preeclampsia-related mortality remains high. Founded in 2020, the company is private and operates in the diagnostics sector, focusing on addressing a critical unmet need in maternal health. The Gates Foundation's backing provides both funding and validation, positioning Kalia Health for further development and potential partnerships. The company's technology aims to enable earlier intervention, improving outcomes for millions of pregnant women worldwide. While still in early stages, the grant and clear clinical need suggest promising upside, though execution risks remain given the regulatory and clinical validation requirements.

Upcoming Catalysts (preview)

• Q4 2026Publication of Gates Foundation-funded preclinical data80% success
• Q2 2027Initiation of pivotal clinical study for urine-based preeclampsia test60% success
• Q1 2027Series A financing round70% success